Bariatric Surgery Cuts Cancer Risk and Mortality by Nearly Half
Clinician's Perspective:
• Reduced Cancer Incidence: The study revealed that patients who underwent bariatric surgery had a 32% lower risk of developing obesity-associated cancers compared to those who did not have surgery.
• Lower Cancer Mortality: Researchers observed a 48% reduction in cancer-related deaths among the surgical group, indicating a significant survival benefit.
• Sustained Weight Loss: At the 10-year mark, the surgery group maintained a weight loss of approximately 25kg (19.2% greater weight loss) more than the nonsurgical control group.
• Dose-Response Relationship: The data suggests a "dose-dependent" effect, meaning that greater amounts of weight loss were directly linked to a lower risk of incident cancer (the number of new cases diagnosed).
• Specific Cancer Reductions: While several cancer types showed a downward trend, Endometrial (lining of the uterus) cancer saw the most significant decrease, with a 53% reduction in risk.
• Comparable Surgical Results: Both Roux-en-Y Gastric Bypass and Sleeve Gastrectomy showed similar effectiveness in reducing cancer risk, suggesting that the weight loss itself is the primary driver of protection.
For years, medical science has recognized a strong link between obesity (the state of having too much body fat) and the development of various malignancies. However, proving that intentional weight loss can actually reverse this risk has been difficult due to the long duration required for cancer to develop. The SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) study provides some of the most robust evidence to date on this connection.
Researchers analyzed data from over 30,000 adult participants with a Body Mass Index (BMI) of 35 or greater. The study compared 5,053 patients who underwent bariatric surgery with 25,265 matched controls who received usual nonsurgical care. By using a median follow-up period of 6.1 years, the study was able to track long-term health outcomes and mortality rates with high precision.
The data reveals that bariatric surgery is associated with a significantly lower risk of 13 types of obesity-associated cancers, including esophageal, colorectal, kidney, and postmenopausal breast cancer. Specifically, the surgical group saw 3.0 cancer events per 1,000 person-years, whereas the nonsurgical group saw 4.6 events. This resulted in an Adjusted Hazard Ratio (a measure of how often an event happens in one group versus another) of 0.68 for cancer incidence and 0.52 for cancer-related death.
The biological mechanisms behind these findings are likely tied to the sustained reversal of metabolic dysfunction. Excess fat tissue often leads to Hyperinsulinemia (excessively high levels of insulin in the blood) and chronic inflammation, both of which can promote tumor growth. Bariatric surgery has been shown to rapidly improve insulin sensitivity and reduce systemic inflammation markers, potentially creating an environment less hospitable to cancer cells.
Interestingly, the study noted that the separation in cancer risk between the two groups only became apparent about six years after the procedure. This suggests that sustained, long-term weight loss is necessary to achieve these protective effects. While nonsurgical interventions like lifestyle changes are often recommended, the researchers noted that many patients struggle to achieve the "dose" of weight loss—typically 20% or more of total body weight—that this study identified as the threshold for significant cancer risk reduction.
In conclusion, the SPLENDID study suggests that for adults with severe obesity, metabolic surgery may offer a powerful tool for the primary prevention of cancer and a reduction in cancer-related mortality.
Evidence Strength: While limited by its observational nature, the study's massive cohort size, rigorous propensity matching, and clear dose-response gradient provide high-quality evidence of a protective association. Final Rating: ★★★★☆
Source: Read the full study
